2025年財務展望

公司發佈了2025年的展望，摘要如下：

• 2025年的收入將在108.5億美元至111.5億美元之間
• 2025年的調整後EBITDA將在5.60億美元至5.90億美元之間
• 2025年的調整後每股收益將在1.60美元至1.85美元之間

公司的2025年展望不包括之前宣佈的Rotech收購、與產品和醫療服務部門有關的任何潛在交易或股票回購活動的影響，幷包含了對當前經濟狀況影響的預期。

支持公司2025年財務指導的關鍵假設包括：

• 毛利率在20.75%至21.25%之間
• 利息支出在1.38億美元至1.42億美元之間
• 調整後的有效稅率在29.0%至30.0%之間
• 稀釋後的加權平均股份約爲8000萬股
• 資本支出（毛額）在2.50億美元至2.70億美元之間
• 商品價格穩定
• 截至2024年12月31日的外匯匯率

2025 Financial Outlook

The Company issued its outlook for 2025; summarized below:

• Revenue for 2025 to be in a range of $10.85 billion to $11.15 billion
• Adjusted EBITDA for 2025 to be in a range of $560 million to $590 million
• Adjusted EPS for 2025 to be in a range of $1.60 to $1.85

The Company's outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products & Healthcare Services segment, or share repurchase activity, and contains assumptions, including current expectations regarding the impact of general economic conditions.

Key assumptions supporting the Company's 2025 financial guidance include:

• Gross margin of 20.75% to 21.25%
• Interest expense of $138 million to $142 million
• Adjusted effective tax rate of 29.0% to 30.0%
• Diluted weighted average shares of ~80 million
• Capital expenditures, gross, of $250 million to $270 million
• Stable commodity prices
• FX rates as of 12/31/2024